Research

Presentations

Verastem ResourcesDYNAMO: A Phase 2 Study of Duvelisib in Patients with Refractory Indolent Non-Hodgkin Lymphoma
Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt, Z Nagy, O Tournilhac, KE Abou-Nassar, M Crump, ED Jacobsen, S de Vos, P Santabarbara, W Shi, L Steelman, ND Wagner-Johnston
December 05, 2016
American Society of Hematology (ASH) 2016 Annual Meeting

Location: San Diego Convention Center, Hall GH
Date and Time: Sunday, December 5, 2016, 6:15 pm PT

Verastem ResourcesPreliminary results in first-line treatment of follicular lymphoma with the oral dual PI3K-delta,gamma inhibitor, duvelisib, in combination with rituximab or obinutuzumab
Carla Casulo, M.D., Assistant Professor, Wilmot Cancer Institute, University of Rochester
December 04, 2016
American Society of Hematology (ASH) 2016 Annual Meeting

Location: San Diego Convention Center, Hall GH
Date and Time: Sunday, December 4, 2016, 6:00 – 8:00 pm PT

Verastem ResourcesInhibition of FAK Exerts Anti-Leukemic Activity and Potentiates ABT-199-Induced Apoptosis in AML
Lead Author: Bing Carter, Ph.D., Associate Professor, Department of Leukemia - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
December 04, 2016
American Society of Hematology (ASH) 2016 Annual Meeting

Location: San Diego Convention Center, Hall GH
Date and Time: Saturday, December 3, 2016, 5:30 – 7:30 pm PT

Verastem ResourcesiMig 2016: Phase 2 Neoadjuvant Study of VS-6063, a FAK Inhibitor, in Subjects with Surgically Resectable Malignant Pleural Mesothelioma
Raphael Bueno, M.D.
May 03, 2016
The International Mesothelioma Interest Group (iMig)

Mini Symposium 10: Novel Targets – Entering in the Clinic (Track: Early Phase Clinical Trials)

Verastem ResourcesAACR 2016: FAK/PYK2 Inhibition Enhances Immune Checkpoint Inhibitor Efficacy
April 18, 2016
AACR 2016

Yan Wang1, Jennifer E. Ring1, Kam Sprott1, David DeNardo2, David T. Weaver1 and Jonathan A. Pachter1

Although durable responses to single agent immune checkpoint inhibitors have been reported, additional approaches are needed to extend this therapeutic benefit to a greater proportion of patients. Combination of immunotherapy agents with tumor microenvironment modulators has the potential to overcome barriers that tumor cells develop to evade the immune system, and provide benefit to a greater proportion of patients. Focal Adhesion Kinase (FAK) and the family member PYK2 are potentially valuable targets due to their roles in regulating key cellular populations in the tumor microenvironment. In addition to targeting cancer stem cells, the FAK/PYK2 dual inhibitors, VS-6063 and VS- 4718, have been shown to inhibit monocyte-derived macrophages, reduce tumor-associated macrophages in xenograft models, and promote a CD8+ T cell-mediated anti-tumor response in squamous cell carcinoma models.

1 Verastem Inc., Boston, MA; 2 Washington University, St. Louis, MO

Verastem ResourcesAACR 2016: FAK Inhibition Re-sensitizes Platinum-resistant Serous Ovarian Cancer
April 18, 2016
AACR 2016

Lisa M. Bean1*, Florian J. Sulzmaier1*, Isabelle Tancioni1, Sean Uryu1, Christine Jean1, Xiao Lei Chen1, Elizabeth G. Kleinschmidt1, Kristen M. Anderson1, Edward A. Cordasco1, Joshua Axelrod1, Vihren N. Kolev2, Jonathan A. Pachter2, Dwayne G. Stupack1 and David D. Schlaepfer1

Focal adhesion kinase (FAK), an intracellular tyrosine kinase, has been linked to mesothelioma and breast cancer stem cell (CSC) survival. Here, we find that FAK activation is elevated in platinum (CP)-resistant ovarian cancer cells and that FAK tyrosine phosphorylation is increased after CP treatment of CPsensitive ovarian cancer cells. Nanomolar levels of FAK inhibitor (VS-4718) selectively blocked CP-resistant ovarian carcinoma methylcellulose colony growth. Oral VS-4718 administration to mice reduces CP-resistant orthotopic tumor burden with a concomitant decrease in tumor-associated aldehyde dehydrogenase (ALDH) activity, a marker of ovarian CSCs. Residual ovarian tumor cells from VS-4718-treated mice exhibit reduced ALDH activity and secondary tumor initiating capacity. CRISPR-mediated FAK knockout or VS- 4718 treated ovarian carcinoma cells exhibit diminished Oct-4 transcription factor and ALDH-1A1 CSC-associated protein marker expression. Coadministration of VS-4718 with CP-taxol chemotherapy reduced CP-resistant tumor burden and exhibited additive inhibitory effects on ovarian carcinoma spheroid growth. As CP activates FAK and that FAK activity sustains ovarian carcinoma CSC phenotypes, our results support the testing of FAK inhibitors in combination with CP to prevent recurrent and chemo-resistant ovarian cancer.

1UC San Diego, Moores Cancer Center; 2Verastem Inc. *Authors contributed equally

Verastem ResourcesKeystone Symposium on Cancer Pathophysiology: Reprograming the Tumor Microenvironment to Facilitate Responses to Immunotherapy
David G. DeNardo, PhD
March 30, 2016
Keystone Symposium on Cancer Pathophysiology

Verastem ResourcesSGO 2016: Standard chemotherapy for ovarian cancer increases expression of cancer stem cell biomarkers and is predictive of survival
March 22, 2016
Annual Meeting on Women's Cancer | SGO

Verastem ResourcesKeystone Symposium on Stem Cells and Cancer: Targeting Cancer Stem Cells with Selective Inhibitors of FAK and PI3K/mTOR
Jonathan Pachter, VP/Head of Research, Verastem
March 10, 2016
Keystone Symposium on Stem Cells and Cancer

Verastem ResourcesEORTC 2015: Focal Adhesion Kinase Inhabition Enables Efficacy of Checkpoint Immunotherapy in Pancreatic Cancer
Hong Jiang1,5, Samarth Hegde1,5, Brett L. Knolhoff1,5, Yu Zhu1,5, John Herndon1,5, Esther Leu4, William Hawkins3,6, Irina M. Shapiro7, David T. Weaver7, Jonathan A. Pachter7, Andrea Wang-Gillam1,6, and David G. DeNardo1,2,5,6
November 06, 2015
EORTC 2015

1Department of Medicine, 2Department of Pathology and Immunology, 3Department of Surgery, 4Division of Biostatistics, 5ICCE Institute, 6Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA
7Verastem Inc., Needham, Massachusetts 02494, USA

Verastem ResourcesEORTC 2015: FAK Inhibition Targets Cancer Stem Cells
Vihren N. Kolev, Yan Wang, Kam Sprott, Irina Shapiro, Jennifer Ring, Jonathan A. Pachter, David T. Weaver
November 06, 2015
EORTC 2015

Verastem Inc., Needham, Massachusetts 02494, USA

Verastem ResourcesEORTC 2015: FAK/PYK2 Inhibitors VS-6063 and VS-4718 Enhance Immune Checkpoint Inhibitor Efficacy
Jennifer E. Ring1, Yajuan Li1, Kam Sprott1, Irina M. Shapiro1, David DeNardo2, Yan Wang1, David T. Weaver1, and Jonathan A. Pachter1
November 06, 2015
EORTC 2015

1Verastem Inc., Boston, MA; 2Washington University, St. Louis, MI

Verastem ResourcesEORTC 2015: Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
November 06, 2015
EORTC 2015

Alan Serrels,1,2 Tom Lund,1 Bryan Serrels,1 Adam Byron,1 Rhoanne C. McPherson,2 Alexander von Kriegsheim,1 Laura Gómez-Cuadrado,1 Marta Canel,1 Morwenna Muir,1 Jennifer E. Ring,3 Eleni Maniati,4 Andrew H Sims,1 Jonathan A. Pachter,3 Valerie G. Brunton,1 Nick Gilbert,5 Stephen M. Anderton,2 Robert J.B. Nibbs,6 and Margaret C. Frame1

1Edinburgh Cancer Research UK Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom. 2MRC Centre for Inflammation Research, The Queens Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom.3Verastem Inc, 215 First Street, Suite 440, Cambridge, Massachusetts, United States of America. 4Queen Mary, University of London, Centre for Cancer and Inflammation, Charterhouse Square, London, United Kingdom. 5MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom. 6Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom.

Verastem ResourcesSITC 2015: Focal Adhesion Kinase Inhabition Enables Efficacy of Checkpoint Immunotherapy in Pancreatic Cancer
Hong Jiang1,5, Samarth Hegde1,5, Brett L. Knolhoff1,5, Yu Zhu1,5, John Herndon1,5, Esther Leu4, William Hawkins3,6, Irina M. Shapiro7, David T. Weaver7, Jonathan A. Pachter7, Andrea Wang-Gillam1,6, and David G. DeNardo1,2,5,6
November 05, 2015
SITC 2015

1Department of Medicine, 2Department of Pathology and Immunology, 3Department of Surgery, 4Division of Biostatistics, 5ICCE Institute, 6Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA
7Verastem Inc., Needham, Massachusetts 02494, USA

Verastem ResourcesSITC 2015: FAK/PYK2 Inhibitors VS-6063 and VS-4718 Enhance Immune Checkpoint Inhibitor Efficacy
Jennifer E. Ring1, Yajuan Li1, Kam Sprott1, Irina M. Shapiro1, David DeNardo2, Yan Wang1, David T. Weaver1, and Jonathan A. Pachter1
November 05, 2015
SITC 2015

1Verastem Inc., Boston, MA; 2Washington University, St. Louis, MI

Verastem ResourcesWCLC 2015: VS-5584 [PI3K/MTOR] and VS-4718 [FAK] Block SCLC Tumor Progression and Cancer Stem Cells
David Weaver
September 09, 2015
2015 World Conference on Lung Cancer

Vice President of Translational Research, Verastem, Inc.

Verastem ResourcesWCLC 2015: Phase II Study Of Defactinib, VS-6063, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients With Kras Mutant Non-Small Cell Lung Cancer (NSCLC)
David E. Gerber, D. Ross Camidge, Daniel Morgensztern, Jeremey Cetnar, Ronan J. Kelly, Suresh S. Ramalingam, David R. Spigel, Woondong Jeong, Pier Scaglioni, Marilyn Li, Mitchell Keegan, Joanna C. Horobin, Timothy F. Burns
September 09, 2015
2015 World Conference on Lung Cancer

Verastem ResourcesWCLC 2015: FAK Inhibitor Defactinib (VS-6063) Targets Mesothelioma Cancer Stem Cells
Jonathan Pachter
September 09, 2015
2015 World Conference on Lung Cancer

Vice President of Research, Verastem, Inc.

Verastem ResourcesWCLC 2015: The Cancer Stem Cell Inhibitors VS-6063 and VS-5584 Exhibit Synergistic Anticancer Activity in Preclinical Models of Mesothelioma
Mitchell Keegan
September 09, 2015
2015 World Conference on Lung Cancer

Vice President of Development, Verastem, Inc.

Verastem ResourcesWCLC 2015: COMMAND: A Phase 2 Randomized, Double-blind, Placebo-Controlled, Multicenter Study of Defactinib as Maintenance Therapy ...
Hedy Lee Kindler1, Dean Fennell2, Paul Baas3, Marjorie Zauderer4, Anna K. Nowak5, Richard J. Gralla6, Takashi Nakano7, Marcelyne Joseney-Antoine8, Anne Poli8, Mitchell Keegan8, Lou Vaickus8
September 09, 2015
2015 World Conference on Lung Cancer

COMMAND: A Phase 2 Randomized, Double-blind, Placebo-Controlled, Multicenter Study of Defactinib as Maintenance Therapy in Subjects with Malignant Pleural Mesothelioma which has Not Progressed on at least 4 Cycles of Pemetrexed/Platinum Therapy

1 University of Chicago, Chicago, USA; 2 University of Leicester, Leicester, United Kingdom; 3 Netherlands Cancer Institute, Amsterdam, Netherlands; 4 Memorial Sloan-Kettering Cancer Center, NYC, USA; 5 University of Western Australia and Sir Charles Gairdner Hospital, Nedlands, Australia; 6 Albert Einstein College of Medicine, Jacobi Medical Center, Bronx, NY, USA; 7 Hyogo College of Medicine, Hyogo, Japan; 8 Verastem, Inc., Boston, USA

Verastem ResourcesWCLC 2015: VS-6063-104: A Phase 1 Dose Escalation Study of VS-5584, a Dual PI3K/mTORInhibitor ...
Udai Banerji1, Dean Anthony Fennell2, Hedy Lee Kindler3, Marjorie Glass Zauderer4, Mitchell Keegan5, Lou Vaickus5
September 09, 2015
2015 IASLC World Conference on Lung Cancer

VS-6063-104: A Phase 1 Dose Escalation Study of VS-5584, a Dual PI3K/mTORInhibitor, Administered with a Fixed Dose of VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects with Relapsed Malignant Mesothelioma

1 Royal Marsden Hospital, Sutton Surrey, UK; 2 University of Leicester, Leicester, UK; 3 University of Chicago, Chicago, IL, USA; 4 Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 5 Verastem Inc., Boston, MA, USA

Verastem ResourcesAACR 2015: FAK Inhibitor VS-6063 (Defactinib) Targets Mesothelioma Cancer Stem Cells, which are Enriched by Standard of Care Chemotherapy
Jonathan A. Pachter1, Vihren N. Kolev1, Laurel Schunselaar2, Mahesh V. Padval1, Irina M. Shapiro1, Raphael Bueno3, Paul Baas2, Qunli Xu1, and David T. Weaver1
April 20, 2015
AACR Annual Meeting 2015

1Verastem Inc., Boston, MA; 2Brigham & Women’s Hospital, Boston, MA; 3Netherlands Cancer Institute, Amsterdam

Verastem ResourcesAACR 2015: FAK and PI3K/mTOR Inhibitors Target Cancer Stem Cells: Implications for SCLC Treatment Strategies
Vihren N. Kolev, Qunli Xu, Mahesh Padval, Jonathan A. Pachter and David T. Weaver Verastem Inc., Boston, MA
April 20, 2015
AACR Annual Meeting 2015

Verastem ResourcesAACR 2015: Targeting Cancer Stem Cells to Impede Tumor Progression
David Weaver
April 20, 2015
AACR Annual Meeting 2015

Verastem ResourcesSABCS 2014: FAK inhibitors VS-6063 (defactinib) and VS-4718 reduce cancer stem cells in models of triple negative breast cancer
Vihren N. Kolev1, Sean McDermott2, Max Wicha2, Jonathan A. Pachter1, Qunli Xu1, David T. Weaver1
December 14, 2014
San Antonio Breast Cancer Symposium

1Verastem, Inc., Boston, MA, 2University of Michigan Cancer Center, Ann Arbor, MI

Verastem ResourcesASH 2014: FAK inhibitors reverse the stromal adhesion phenotype of Ikaros-mutant B-ALL, induce apoptosis, and synergize with ABL1 TKIs: A new paradigm for pathogenesis & therapy of high-risk B-ALL
December 08, 2014
56th ASH Annual Meeting & Exposition

Verastem ResourcesASH 2014: PYK2 Inhibitors Sensitize Hypoxia-Induced Drug Resistant Multiple Myeloma Cell
Barbara Muz1, Maurizio Buggio1, Feda Azab1, Anthony F. Trombino2, Mahesh Padval2 and Abdel Kareem Azab1
December 08, 2014
56th ASH Annual Meeting & Exposition

1Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, Saint Louis MO, USA; 2 Verastem, Inc., Boston MA, USA

Verastem ResourcesASH 2014: Targeting PYK2 Mediates Microenvironment-Specific Myeloma Cell Death
Mark B. Meads1, Bin Fang2, Linda Mathews1, Jennifer Gemmer1, Liang Nong1, Ismael Rosado - Lopez1, Tuan Nguyen1, Jennifer E. Ring7, William Matsui5, A. Robert MacLeod6 , Jonathan A. Pachter7, Lori A. Hazlehurst3, John M. Koomen2,3, and Kenneth H. Shain1,4
December 07, 2014
56th ASH Annual Meeting & Exposition

Departments of Chemical Biology and Molecular Medicine 1, Proteomics 2, Molecular Oncology 3, and Malignant Hematology 4 at Moffitt Cancer Center and Research Institute, Tampa, Florida 5, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland 6 ISIS Pharmaceuticals, Carlsbad, California & 7 Verastem, Inc, Needham, Massachusetts

Verastem ResourcesASH 2014: Proline-Rich Tyrosine Kinase (PYK2) Promotes Tumor Progression in Multiple Myeloma (MM) and Represents a Novel Target for Therapy in MM
Y Zhang, M Moschetta, D Huynh, YT Tai, Y Zhang, W Zhang, Y Mishima, JE. Ring, WF Tam, Q Xu, P Maiso, M Reagan, I Sahin, A Sacco, S Manier, Y Aljawai, S Glavey, NC Munshi, KC Anderson, J Pachter, AM. Roccaro, IM. Ghobrial Dana
December 07, 2014
56th ASH Annual Meeting & Exposition

Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, MA; Verastem Inc., Cambridge, MA

Verastem ResourcesASH 2014: VS-4718, a Potent Focal Adhesion Kinase (FAK) Inhibitor, Exhibits Anticancer Activity in Leukemia Models in Vitro and in Vivo
Winnie F. Tam, PhD, Jennifer E. Ring, Anthony F. Trombino, PhD, Jonathan A. Pachter, PhD, Mahesh V. Padval, PhD, Qunli Xu, PhD, David T. Weaver, PhD

December 07, 2014
56th ASH Annual Meeting & Exposition

Verastem Inc., Boston, MA

Verastem ResourcesEORTC 2014: FAK Inhibitor VS-6063 (Defactinib) Targets Mesothelioma Cancer Stem Cells Which Are Enriched by Standard of Care Chemotherapy
Jonathan A. Pachter1, Vihren N. Kolev1, Laurel Schunselaar3, Irina M. Shapiro1, Raphael Bueno2, Paul Baas3, David T. Weaver1 and Qunli Xu1
November 21, 2014
EORTC, Barcelona November 2014

1Verastem Inc., Boston, MA; 2Brigham & Women’s Hospital, Boston, MA; 3Netherlands Cancer Institute, Amsterdam

Verastem ResourcesEORTC 2014: A first-in-Asian phase I dose escalation study to evaluate the safety and pharmacokinetics of VS-6063 (defactinib), a focal adhesion kinase inhibitor in subjects with non-hematologic malignancies
1Toshio Shimizu, MD, PhD, 2Hidemi Aida, PhD, 2Chiaki Hashii, 3Joanna Horobin, MB, ChB, 3Mitchell Keegan, PhD, 3Mahesh Padval, PhD, 3Anne Poli, 3Lindsey Wilson, 1Kazuhiko Nakagawa, MD, PhD

November 21, 2014
EORTC, Barcelona November 2014

1Phase 1 Clinical Trials Program, Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka, Japan; 2Japan Clinical Research Operations (JCRO), Tokyo, Japan; 3Verastem, Inc., Boston, MA, USA

Verastem ResourcesEORTC 2014: PI3K/mTOR inhibitor VS-5584 targets cancer stem cells and prevents tumor regrowth after chemotherapy in preclinical models of small cell lung cancer
Vihren N. Kolev1, Mahesh V. Padval1, Quentin G.Wright1, Jill Ricono2, David T. Weaver1, Jonathan A. Pachter1, and Qunli Xu1
November 21, 2014
EORTC, Barcelona November 2014

1Verastem Inc., Boston, MA; 2Molecular Response, San Diego, CA

Verastem ResourcesEORTC 2014: The cancer stem cell inhibitors VS-6063 (defactinib) and VS-5584 exhibit synergistic anticancer activity in preclinical models of mesothelioma
Qunli Xu1, Winnie F. Tam1, Christian M. Vidal1, Vihren N. Kolev1, Yuwaraj Kadariya2, Craig W. Menges2, Joseph R. Testa2, and Jonathan A. Pachter1
November 21, 2014
EORTC, Barcelona November 2014

1Verastem Inc., Boston, MA; 2Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA

Verastem ResourcesiMig 2014: FAK Inhibitor VS-6063 (defactinib) Targets Mesothelioma Cancer Stem Cells which are Enriched by Standard of Care Chemotherapy
Paul Baas, Department of Thorax Oncology Netherlands Cancer Institute, Amsterdam
October 23, 2014
iMig, Cape Town October 2014

Verastem ResourcesiMig 2014: Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS-6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Subjects with Resectable MPM
Raphael Bueno1, Ritu R Gill1, Julianne Barlow1, David M Jackman1, Beow Y Yeap1, David Weaver2, Mahesh Padval2, Rachel Sorensen2, Mitchell Keegan2
October 23, 2014
iMig, Cape Town October 2014

1. Brigham and Women’s Hospital, Boston, MA, USA; 2. Verastem, Inc., Boston, MA, USA

Verastem ResourcesiMig 2014: The Cancer Stem Cell Inhibitors VS-6063 (defactinib) and VS-5584 Exhibit Synergistic Anticancer Activity in Preclinical Models of Mesothelioma
Mitchell Keegan, VP Development – Verastem
October 23, 2014
iMig, Cape Town October 2014

Verastem ResourcesiMig 2014: COMMAND : A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Defactinib as Maintenance Therapy
Paul Baas1, Dean Fennell2, Richard J. Gralla3, Hedy Kindler4, Lee M. Krug5, Anna K. Nowak6, Lawrence H. Schwartz7, Mitchell Keegan8, Joanna C. Horobin8
October 23, 2014
iMig, Cape Town October 2014

1. The Netherlands Cancer, Amsterdam NL; 2. University of Leicester, Leicester UK; 3. Albert Einstein College of Medicine, Bronx, NY USA; 4. University of Chicago, Chicago, IL USA; 5. Memorial Sloan-Kettering Cancer Center, New York, NY USA; 6. University of Western Australia, Perth, AU; 7. Columbia University College of Physicians and Surgeons, New York USA; 8. Verastem, Needham, MA USA

Verastem ResourcesVS5584 anti-tumor activity in xenograft models AACR 2014
Anthony F. Trombino, Mahesh V. Padval, Quentin F. Wright and Qunli Xu
April 07, 2014
AACR 2014

Verastem ResourcesVS6063 TNBC CSC AACR 2014
Qunli Xu, Vihren N. Kolev, Quentin G. Wright, Jennifer E. Ring, Christian M. Vidal, Irina M. Shapiro, David T. Weaver, Mahesh V. Padval and Jonathan A. Pachter
April 07, 2014
AACR 2014

Verastem ResourcesCombined inhibition of PI3K isoforms and mTOR kinase is critical for cancer stem cell inhibition by VS-5584
Vihren N. Kolev, Quentin G. Wright, David T. Weaver, Jennifer E. Ring, Christian M. Vidal, Mahesh V. Padval, Jonathan A. Pachter and Qunli Xu
April 07, 2014
AACR 2014

Verastem ResourcesFAK Inhibitor VS-4718 Attenuates Breast Cancer Stem Cell Function in vitro and in vivo
Vihren N. Kolev, Quentin G. Wright, Christian M. Vidal, Irina M. Shapiro, Mahesh V. Padval, Mitchell Keegan, Qunli Xu and Jonathan A. Pachter
December 08, 2012
P6-11-09; 2012 San Antonio Breast Cancer Symposium

Verastem ResourcesThe Cancer Stem Cell-Targeting Wnt Inhibitor VS-507 Reduces Breast Cancer Growth and Metastasis
Jennifer E. Ring, Vihren N. Kolev, Christian M. Vidal, Irina M. Shapiro, Mahesh V. Padval, Mitchell Keegan, Jonathan A. Pachter, and Qunli Xu
December 08, 2012
P6-11-07; 2012 San Antonio Breast Cancer Symposium

Verastem ResourcesThe FAK Inhibitor VS-4718 Attenuates Breast Cancer Stem Cell Function and Inhibits Tumor Growth in vivo
Qunli Xu, Vihren N. Kolev, Quentin G. Wright, Christian M. Vidal, Irina M. Shapiro, Jennifer E. Ring, Mahesh V. Padval, Mitchell Keegan, and Jonathan A. Pachter
November 09, 2012
400; 2012 EORTC/AACR Molecular Targets Meeting

Verastem ResourcesThe Pan-PI3K/mTOR Kinase Inhibitor VS-5584 Preferentially Targets Cancer Stem Cells in Breast Cancer Models
Jonathan A. Pachter, Vihren N. Kolev, Alissa A. Neill, Quentin Wright, Mahesh V. Padval & Qunli Xu
November 09, 2012
405; 2012 EORTC/AACR Molecular Targets Meeting

Verastem ResourcesFAK Inhibitor VS-4718 Preferentially Attenuates Growth of Malignant Mesotheliomas with NF2 Mutation: Role of Cancer Stem Cells
Irina M. Shapiro, Vihren N. Kolev, Christian M. Vidal, Mitchell Keegan1, Qunli Xu, Craig Menges, Joseph R. Testa and Jonathan A. Pachter
September 14, 2012
P1.14; International Mesothelioma Interest Group

Verastem ResourcesGene Expression and Alternative Splicing Signatures Discriminate Breast Cancer Stem Cells from Fibroblasts
David T. Weaver, Irina M. Shapiro, Alan G. Derr, Daniel W. Paterson, Jonathan A. Pachter
June 04, 2012
1057; American Society of Clinical Oncology

Verastem ResourcesThe FAK Inhibitors VS-4718 and VS-5095 Attenuate Breast Cancer Stem Cell Function in vitro and Tumor Growth in vivo
Qunli Xu, Christian M. Vidal, Jennifer E. Ring, Vihren N. Kolev, Irina M. Shapiro, Alissa A. Neill, Kevin T. Sprott, Mitchell Keegan, Daniel W. Paterson, Mahesh V. Padval and Jonathan A. Pachter.
April 02, 2012
LB-192; American Association for Cancer Research Annual Meeting

Verastem ResourcesThe Wnt Inhibitor VS-507 Reduces Cancer Stem Cell Function in vitro and Tumorigenicity in Mice
Jonathan A. Pachter, Jennifer E. Ring, Vihren N. Kolev, Alissa A. Neill, Christian M. Vidal, Brian T. Sullivan, Kevin T. Sprott, Mahesh V. Padval and Qunli Xu
April 02, 2012
LB-194; American Association for Cancer Research Annual Meeting

Verastem ResourcesAn Alternative Splicing Signature that Identifies Breast Cancer Stem Cells
Irina M. Shapiro, Jiangwen Zhang, Alan G. Derr, Christian M. Vidal, Alissa A. Neill, Qunli Xu, Daniel W. Paterson, Jonathan A. Pachter and David T. Weaver
April 02, 2012
LB-197; American Association for Cancer Research Annual Meeting